A Multi-Center, Double-blind, Randomized, Placebo Controlled, Parallel Group Study of the Effect of Dalcetrapib on Atherosclerotic Disease Progression As Measured by Coronary Intravascular Ultrasound, Carotid B-Mode Ultrasound and Coronary Angiography.

Trial Profile

A Multi-Center, Double-blind, Randomized, Placebo Controlled, Parallel Group Study of the Effect of Dalcetrapib on Atherosclerotic Disease Progression As Measured by Coronary Intravascular Ultrasound, Carotid B-Mode Ultrasound and Coronary Angiography.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2016

At a glance

  • Drugs Dalcetrapib (Primary)
  • Indications Atherosclerosis; Coronary artery disease; Dyslipidaemias
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms dal-PLAQUE-2
  • Sponsors Roche
  • Most Recent Events

    • 18 Jul 2016 According to a DalCor Pharmaceuticals media release, data from this study was published in Circulation, Cardiovascular Genetics.
    • 07 May 2012 Status changed from active, no longer recruiting to discontinued as reported by Roche.
    • 21 Apr 2012 New source identified and integrated (European Clinical Trials Database: EudraCT2009-017725-19).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top